Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 18, 2011

View Archived Issues

Neramexane mesilate is safe and well tolerated in subjects with tinnitus

RBC-mimicking hydrogel microparticles display improved biodistribution and circulation times

VKORC1 gene variations are associated with bone mineral density

MMRF and Synta Pharma to codevelop ganetespib for multiple myeloma

Lorus Therapeutics begins phase I trial of anticancer candidate LOR-253

Colesevelam has beneficial effects in patients with type 1 diabetes

Microtubule-associated protein 2 as a biomarker for traumatic brain injury

Bikam Pharmaceuticals presents new opsin ligands

New inhibitors of osteoclast differentiation/stimulation claimed

Vaximm obtains funding for phase I testing of VXM-01 vaccine

GSK patents new inhibitors of serotonin, dopamine and norepinephrine reuptake

Lilly and Boehringer Ingelheim enter global diabetes alliance

FDA agrees to SPA for phase III trials of netupitant/palonosetron as antiemetic

Epizyme and GSK join to develop agents targeting histone methyltransferases

GSK develops novel lysophospholipid S1P1 receptor agonists

Discovery Labs to prepare complete response to gain FDA approval for Surfaxin

Galapagos provides update on arthritis alliance with GSK

FDA approves new formulation of acetylcysteine injection

Risk of severe liver injury to be added to Multaq labels

Phase I trial to evaluate hydroxychloroquine to block autophagy in cancer

Phase I/II trial of Mologen's MGN-1601 in renal cancer cleared to admit all patients

Merck Serono and Domain Therapeutics join to develop agents for Parkinson's disease

Phase II trial of ADXS-11-001 in cervical dysplasia advances

Health Canada requests more information from Osiris regarding Prochymal approval

Bayer and Regeneron initiate phase III Asian trial of VEGF Trap-Eye

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...